Related Experiment Video
Updated: May 13, 2026

Assessment of Kidney Function in Mouse Models of Glomerular Disease
Published on: June 30, 2018
Evaluation of liver and kidney function in favism patients
Akbar Dorgalaleh1, Muhammad Shahid Shahzad, Mohammad Reza Younesi
1MSc of Hematology, Hematology Department, Allied Medical School, Tehran University of Medical Sciences, Tehran, Iran. dorgalaleh.1390@yahoo.com.
Background:
G6PD deficiency is the most common enzymopathy of red blood cells. The clinical symptoms of favism are jaundice, hematuria and haemolytic anaemia that seem to affect liver and kidney in long term. Thus we evaluate kidney and liver function of favism patients in an endemic area of the disease with a high rate of fava beans cultivation.
Methods:
This study was performed on favism patients and healthy controls referring to Iranshahr central hospital. Liver and kidney function tests were performed.
Results:
The results showed a statistically significant difference between these two groups (p <0.05) for liver function tests, (AST, ALT and ALP), but not for renal tests (BUN and creatinine) (p >0.05).
Conclusion:
Due to abnormalities were seen in the liver function tests of these patients, we suggest that these tests be regularly performed for favism patients who are constantly exposed to oxidant agents.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Serum Studies: Renal Function Tests
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

